Understand the source comparison
Best Peptides for Meniscus Tear: Research Comparison
BPC-157 VEGF upregulation, collagen type I synthesis, FAK-paxillin pathway activation Tendons, ligaments, fibrocartilage Rodent tendon studies show 30–40% faster healing at 14 days vs controls 200–500 mcg/day subcutaneous or local injection Subcutaneous near i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, collagen type I synthesis, FAK-paxillin pathway activation
- Tendons, ligaments, fibrocartilage
- Rodent tendon studies show 30–40% faster healing at 14 days vs controls
- 200–500 mcg/day subcutaneous or local injection
- Subcutaneous near injury site or systemic
- Strongest evidence for vascularised soft tissue. Meniscus applicability is mechanistically plausible but unproven in humans
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration, anti-inflammatory cytokine modulation
- Muscle, cardiac tissue, connective tissue
- Equine tendonitis trials and cardiac repair studies show improved cell migration and reduced inflammation
- 2–5 mg twice weekly for 4–6 weeks
- Subcutaneous systemic injection
- Broad anti-inflammatory and repair signaling. Less tissue-specific than BPC-157, longer half-life allows less frequent dosing
- GHK-Cu
- TGF-β modulation, matrix metalloproteinase activity, collagen/GAG synthesis
- Dermal tissue, extracellular matrix remodelling
- Dermal wound studies show 70% increase in collagen synthesis, improved scar remodelling
- 1–3 mg/day subcutaneous
- Subcutaneous near injury or systemic
- Best for matrix remodelling and scar tissue conversion. Slower timeline (8–12 weeks) than acute repair peptides
- The comparison highlights a pattern: BPC-157 targets acute tissue repair through angiogenesis and collagen deposition. TB-500 supports cellular migration and inflammation resolution across multiple tissue types. GHK-Cu excels at long-term matrix remodelling and scar tissue conversion. A researcher designing a protocol might sequence them. TB-500 in the first 2–4 weeks to control inflammation and recruit repair cells, BPC-157 in weeks 3–8 to accelerate collagen synthesis, GHK-Cu in weeks 6–16 to optimise extracellular matrix structure. None of this has been validated in human meniscal injuries.